Header Logo

Connection

Jeffrey Kordower to Animals

Back to Details
This is a "connection" page, showing publications Jeffrey Kordower has written about Animals.
Jeffrey Kordower
Connection Strength
5.788
Animals
  1. In situ proximity labeling identifies Lewy pathology molecular interactions in the human brain. Proc Natl Acad Sci U S A. 2022 02 01; 119(5).
    View in: PubMed
    Score: 0.110
  2. A historical review of multiple system atrophy with a critical appraisal of cellular and animal models. J Neural Transm (Vienna). 2021 10; 128(10):1507-1527.
    View in: PubMed
    Score: 0.108
  3. Enhanced CNS transduction from AAV.PHP.eB infusion into the cisterna magna of older adult rats compared to AAV9. Gene Ther. 2022 06; 29(6):390-397.
    View in: PubMed
    Score: 0.104
  4. GDNF signaling in subjects with minimal motor deficits and Parkinson's disease. Neurobiol Dis. 2021 06; 153:105298.
    View in: PubMed
    Score: 0.104
  5. Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease. Neurobiol Dis. 2021 01; 148:105184.
    View in: PubMed
    Score: 0.102
  6. Mitomycin-C treatment during differentiation of induced pluripotent stem cell-derived dopamine neurons reduces proliferation without compromising survival or function in?vivo. Stem Cells Transl Med. 2021 02; 10(2):278-290.
    View in: PubMed
    Score: 0.101
  7. Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes. Brain. 2019 11 01; 142(11):3565-3579.
    View in: PubMed
    Score: 0.094
  8. Immunotherapy in Parkinson's disease: Current status and future directions. Neurobiol Dis. 2019 12; 132:104587.
    View in: PubMed
    Score: 0.093
  9. Spreading of alpha-synuclein - relevant or epiphenomenon? J Neurochem. 2019 09; 150(5):605-611.
    View in: PubMed
    Score: 0.092
  10. Temporal evolution of microglia and a-synuclein accumulation following foetal grafting in Parkinson's disease. Brain. 2019 06 01; 142(6):1690-1700.
    View in: PubMed
    Score: 0.092
  11. Focused ultrasound opening of the blood-brain barrier for treatment of Parkinson's disease. Mov Disord. 2019 09; 34(9):1274-1278.
    View in: PubMed
    Score: 0.092
  12. Parkinson's disease gene therapy: Will focused ultrasound and nanovectors be the next frontier? Mov Disord. 2019 09; 34(9):1279-1282.
    View in: PubMed
    Score: 0.091
  13. Disease Modification for Parkinson's Disease: Axonal Regeneration and Trophic Factors. Mov Disord. 2018 05; 33(5):678-683.
    View in: PubMed
    Score: 0.085
  14. Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology. Neurobiol Dis. 2018 04; 112:106-118.
    View in: PubMed
    Score: 0.083
  15. Disease Modification Through Trophic Factor Delivery. Methods Mol Biol. 2018; 1780:525-547.
    View in: PubMed
    Score: 0.083
  16. Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol. 2017 12; 298(Pt B):225-235.
    View in: PubMed
    Score: 0.082
  17. Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates. Acta Neuropathol Commun. 2017 06 16; 5(1):47.
    View in: PubMed
    Score: 0.080
  18. Cryopreservation Maintains Functionality of Human iPSC Dopamine Neurons and Rescues Parkinsonian Phenotypes In?Vivo. Stem Cell Reports. 2017 07 11; 9(1):149-161.
    View in: PubMed
    Score: 0.080
  19. Aging and Parkinson's disease: Different sides of the same coin? Mov Disord. 2017 Jul; 32(7):983-990.
    View in: PubMed
    Score: 0.080
  20. a-Synuclein nonhuman primate models of Parkinson's disease. J Neural Transm (Vienna). 2018 03; 125(3):385-400.
    View in: PubMed
    Score: 0.079
  21. What would Dr. James Parkinson think today? parcelling out the circuitry of levodopa-induced dyskinesias. Mov Disord. 2017 04; 32(4):483-484.
    View in: PubMed
    Score: 0.079
  22. Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias. J Comp Neurol. 2017 02 15; 525(3):498-512.
    View in: PubMed
    Score: 0.076
  23. Alterations in Activity-Dependent Neuroprotective Protein in Sporadic and Experimental Parkinson's Disease. J Parkinsons Dis. 2016; 6(1):77-97.
    View in: PubMed
    Score: 0.072
  24. Trophic factors for Parkinson's disease: To live or let die. Mov Disord. 2015 Nov; 30(13):1715-24.
    View in: PubMed
    Score: 0.072
  25. Parkinson's disease and prion disease: Straining the comparison. Mov Disord. 2015 Nov; 30(13):1727.
    View in: PubMed
    Score: 0.072
  26. Alpha-synuclein propagation: New insights from animal models. Mov Disord. 2016 Feb; 31(2):161-8.
    View in: PubMed
    Score: 0.071
  27. The prion hypothesis of Parkinson's disease. Curr Neurol Neurosci Rep. 2015 May; 15(5):28.
    View in: PubMed
    Score: 0.069
  28. Gene therapy for Parkinson's disease: still a hot topic? Neuropsychopharmacology. 2015 Jan; 40(1):255-6.
    View in: PubMed
    Score: 0.068
  29. Special issue on stem cells. J Comp Neurol. 2014 Aug 15; 522(12):2689-90.
    View in: PubMed
    Score: 0.066
  30. Peripheral alpha-synuclein and Parkinson's disease. Mov Disord. 2014 Jul; 29(8):963-6.
    View in: PubMed
    Score: 0.065
  31. The prion hypothesis of Parkinson's disease: this hot topic just got hotter. Mov Disord. 2014 Jul; 29(8):988.
    View in: PubMed
    Score: 0.065
  32. Abnormal alpha-synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental Parkinson's disease. Neurobiol Dis. 2014 Sep; 69:1-14.
    View in: PubMed
    Score: 0.065
  33. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. Mov Disord. 2014 Jul; 29(8):999-1009.
    View in: PubMed
    Score: 0.062
  34. Cell therapy for Parkinson's disease: what next? Mov Disord. 2013 Jan; 28(1):110-5.
    View in: PubMed
    Score: 0.059
  35. Introduction: gene therapy has gone from a pipe dream to clinical reality. Neurobiol Dis. 2012 Nov; 48(2):151-2.
    View in: PubMed
    Score: 0.057
  36. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain. 2012 Jul; 135(Pt 7):2058-73.
    View in: PubMed
    Score: 0.057
  37. Gene therapy for Huntington's disease. Neurobiol Dis. 2012 Nov; 48(2):243-54.
    View in: PubMed
    Score: 0.055
  38. GDNF family ligands: a potential future for Parkinson's disease therapy. CNS Neurol Disord Drug Targets. 2011 Sep 01; 10(6):703-11.
    View in: PubMed
    Score: 0.054
  39. Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat Rev Neurosci. 2011 06; 12(6):359-66.
    View in: PubMed
    Score: 0.053
  40. Transfer of host-derived a synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis. 2011 Sep; 43(3):552-7.
    View in: PubMed
    Score: 0.052
  41. Cell transplantation and gene therapy in Parkinson's disease. Mt Sinai J Med. 2011 Jan-Feb; 78(1):126-58.
    View in: PubMed
    Score: 0.051
  42. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord. 2011 Jan; 26(1):27-36.
    View in: PubMed
    Score: 0.051
  43. a-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease. Neurobiol Dis. 2011 Jan; 41(1):71-82.
    View in: PubMed
    Score: 0.050
  44. Long-term gonadal hormone treatment and endogenous neurogenesis in the dentate gyrus of the adult female monkey. Exp Neurol. 2010 Jul; 224(1):252-7.
    View in: PubMed
    Score: 0.049
  45. Lewy body pathology in fetal grafts. Ann N Y Acad Sci. 2010 Jan; 1184:55-67.
    View in: PubMed
    Score: 0.048
  46. Gene therapy for Parkinson's disease. Mov Disord. 2010; 25 Suppl 1:S161-73.
    View in: PubMed
    Score: 0.048
  47. Neurotrophic factor therapy for Parkinson's disease. Prog Brain Res. 2010; 184:237-64.
    View in: PubMed
    Score: 0.048
  48. Are growth factors the answer? Parkinsonism Relat Disord. 2009 Dec; 15 Suppl 3:S176-80.
    View in: PubMed
    Score: 0.047
  49. Modeling Parkinson's disease. Ann Neurol. 2009 Oct; 66(4):432-6.
    View in: PubMed
    Score: 0.047
  50. Propagation of host disease to grafted neurons: accumulating evidence. Exp Neurol. 2009 Dec; 220(2):224-5.
    View in: PubMed
    Score: 0.047
  51. Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther. 2010 Mar; 18(3):579-87.
    View in: PubMed
    Score: 0.047
  52. Injectable hydrogels providing sustained delivery of vascular endothelial growth factor are neuroprotective in a rat model of Huntington's disease. Neurotox Res. 2010 Jan; 17(1):66-74.
    View in: PubMed
    Score: 0.046
  53. Celebrating neural repair. J Comp Neurol. 2009 Jul 01; 515(1):1-3.
    View in: PubMed
    Score: 0.046
  54. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009 Sep; 35(3):385-98.
    View in: PubMed
    Score: 0.046
  55. Trophic factors therapy in Parkinson's disease. Prog Brain Res. 2009; 175:201-16.
    View in: PubMed
    Score: 0.045
  56. Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease. Neurobiol Dis. 2009 Apr; 34(1):40-50.
    View in: PubMed
    Score: 0.045
  57. Future of cell and gene therapies for Parkinson's disease. Ann Neurol. 2008 Dec; 64 Suppl 2:S122-38.
    View in: PubMed
    Score: 0.044
  58. Regulatable promoters and gene therapy for Parkinson's disease: is the only thing to fear, fear itself? Exp Neurol. 2008 Jan; 209(1):34-40.
    View in: PubMed
    Score: 0.041
  59. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord. 2007 Jun 15; 22(8):1124-32.
    View in: PubMed
    Score: 0.040
  60. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease. Neurobiol Dis. 2007 May; 26(2):375-84.
    View in: PubMed
    Score: 0.039
  61. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis. 2007 Apr; 26(1):56-65.
    View in: PubMed
    Score: 0.039
  62. Animal models of Huntington's disease. ILAR J. 2007; 48(4):356-73.
    View in: PubMed
    Score: 0.039
  63. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol. 2006 Dec; 60(6):706-15.
    View in: PubMed
    Score: 0.039
  64. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis. 2007 Jan; 25(1):134-49.
    View in: PubMed
    Score: 0.038
  65. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann Neurol. 2006 Aug; 60(2):264-8.
    View in: PubMed
    Score: 0.038
  66. Extensive neuroprotection by choroid plexus transplants in excitotoxin lesioned monkeys. Neurobiol Dis. 2006 Aug; 23(2):471-80.
    View in: PubMed
    Score: 0.037
  67. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9345-50.
    View in: PubMed
    Score: 0.037
  68. Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease. Neurology. 2006 May 23; 66(10 Suppl 4):S89-103.
    View in: PubMed
    Score: 0.037
  69. Neural repair strategies for Parkinson's disease: insights from primate models. Cell Transplant. 2006; 15(3):251-65.
    View in: PubMed
    Score: 0.036
  70. RET expression does not change with age in the substantia nigra pars compacta of rhesus monkeys. Neurobiol Aging. 2006 Jun; 27(6):857-61.
    View in: PubMed
    Score: 0.035
  71. Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism. Exp Neurol. 2005 Feb; 191 Suppl 1:S60-7.
    View in: PubMed
    Score: 0.034
  72. Human neural stem cell transplants improve motor function in a rat model of Huntington's disease. J Comp Neurol. 2004 Jul 19; 475(2):211-9.
    View in: PubMed
    Score: 0.033
  73. Effects of estrogen replacement therapy on cholinergic basal forebrain neurons and cortical cholinergic innervation in young and aged ovariectomized rhesus monkeys. J Comp Neurol. 2004 Apr 26; 472(2):193-207.
    View in: PubMed
    Score: 0.032
  74. Primate models of Parkinson's disease. Exp Neurol. 2003 Oct; 183(2):258-62.
    View in: PubMed
    Score: 0.031
  75. Nigral-specific increase in ser31 phosphorylation compensates for tyrosine hydroxylase protein and nigrostriatal neuron loss: Implications for delaying parkinsonian signs. Exp Neurol. 2023 10; 368:114509.
    View in: PubMed
    Score: 0.031
  76. GFAP knockout mice have increased levels of GDNF that protect striatal neurons from metabolic and excitotoxic insults. J Comp Neurol. 2003 Jun 30; 461(3):307-16.
    View in: PubMed
    Score: 0.030
  77. Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp Neurol. 2003 Jun; 181(2):213-23.
    View in: PubMed
    Score: 0.030
  78. Knockout of p75NTR does not alter the viability of striatal neurons following a metabolic or excitotoxic injury. J Mol Neurosci. 2003 Apr; 20(2):93-102.
    View in: PubMed
    Score: 0.030
  79. In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease. Ann Neurol. 2003; 53 Suppl 3:S120-32; discussion S132-4.
    View in: PubMed
    Score: 0.029
  80. Etiology of Parkinson's disease: Genetics and environment revisited. Proc Natl Acad Sci U S A. 2002 Oct 29; 99(22):13972-4.
    View in: PubMed
    Score: 0.029
  81. Stimulation of synaptic activity promotes TFEB-mediated clearance of pathological MAPT/Tau in cellular and mouse models of tauopathies. Autophagy. 2023 02; 19(2):660-677.
    View in: PubMed
    Score: 0.029
  82. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci. 2002 Jun 15; 22(12):4942-54.
    View in: PubMed
    Score: 0.028
  83. Excitotoxic and metabolic damage to the rodent striatum: role of the P75 neurotrophin receptor and glial progenitors. J Comp Neurol. 2002 Mar 18; 444(4):291-305.
    View in: PubMed
    Score: 0.028
  84. Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease. Neurosurgery. 2002 Jan; 50(1):137-45; discussion 145-6.
    View in: PubMed
    Score: 0.027
  85. Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF. Prog Brain Res. 2002; 138:421-32.
    View in: PubMed
    Score: 0.027
  86. SeqStain is an efficient method for multiplexed, spatialomic profiling of human and murine tissues. Cell Rep Methods. 2021 06 21; 1(2).
    View in: PubMed
    Score: 0.026
  87. A novel tau-based rhesus monkey model of Alzheimer's pathogenesis. Alzheimers Dement. 2021 06; 17(6):933-945.
    View in: PubMed
    Score: 0.026
  88. Inflammation in Experimental Models of a-Synucleinopathies. Mov Disord. 2021 01; 36(1):37-49.
    View in: PubMed
    Score: 0.025
  89. Anti-a-synuclein ASO delivered to monoamine neurons prevents a-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys. EBioMedicine. 2020 Sep; 59:102944.
    View in: PubMed
    Score: 0.025
  90. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease. J Neurosci. 2020 04 29; 40(18):3675-3691.
    View in: PubMed
    Score: 0.024
  91. Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson's disease models. J Clin Invest. 2020 02 03; 130(2):904-920.
    View in: PubMed
    Score: 0.024
  92. T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease. Acta Neuropathol. 2020 05; 139(5):855-874.
    View in: PubMed
    Score: 0.024
  93. Does Developmental Variability in the Number of Midbrain Dopamine Neurons Affect Individual Risk for Sporadic Parkinson's Disease? J Parkinsons Dis. 2020; 10(2):405-411.
    View in: PubMed
    Score: 0.024
  94. GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. J Parkinsons Dis. 2020; 10(3):875-891.
    View in: PubMed
    Score: 0.024
  95. Widespread Striatal Delivery of GDNF from Encapsulated Cells Prevents the Anatomical and Functional Consequences of Excitotoxicity. Neural Plast. 2019; 2019:6286197.
    View in: PubMed
    Score: 0.023
  96. Demonstration of prion-like properties of mutant huntingtin fibrils in both in vitro and in vivo paradigms. Acta Neuropathol. 2019 06; 137(6):981-1001.
    View in: PubMed
    Score: 0.023
  97. Loss of One Engrailed1 Allele Enhances Induced a-Synucleinopathy. J Parkinsons Dis. 2019; 9(2):315-326.
    View in: PubMed
    Score: 0.022
  98. Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease. Neurobiol Dis. 2020 02; 135:104352.
    View in: PubMed
    Score: 0.022
  99. Role of TLR4 in the gut-brain axis in Parkinson's disease: a translational study from men to mice. Gut. 2019 05; 68(5):829-843.
    View in: PubMed
    Score: 0.022
  100. Detecting Alpha Synuclein Seeding Activity in Formaldehyde-Fixed MSA Patient Tissue by PMCA. Mol Neurobiol. 2018 Nov; 55(11):8728-8737.
    View in: PubMed
    Score: 0.021
  101. Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease. Sci Transl Med. 2016 12 07; 8(368):368ra174.
    View in: PubMed
    Score: 0.019
  102. Is Axonal Degeneration a Key Early Event in Parkinson's Disease? J Parkinsons Dis. 2016 10 19; 6(4):703-707.
    View in: PubMed
    Score: 0.019
  103. Neutralization of RANTES and Eotaxin Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson Disease. J Biol Chem. 2016 07 15; 291(29):15267-81.
    View in: PubMed
    Score: 0.019
  104. Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy. Brain. 2015 Dec; 138(Pt 12):3555-66.
    View in: PubMed
    Score: 0.018
  105. PGC-1a Promoter Methylation in Parkinson's Disease. PLoS One. 2015; 10(8):e0134087.
    View in: PubMed
    Score: 0.018
  106. Analysis of YFP(J16)-R6/2 reporter mice and postmortem brains reveals early pathology and increased vulnerability of callosal axons in Huntington's disease. Hum Mol Genet. 2015 Sep 15; 24(18):5285-98.
    View in: PubMed
    Score: 0.017
  107. Attenuation of microglial RANTES by NEMO-binding domain peptide inhibits the infiltration of CD8(+) T cells in the nigra of hemiparkinsonian monkey. Neuroscience. 2015 Aug 27; 302:36-46.
    View in: PubMed
    Score: 0.017
  108. Neonatal immune-tolerance in mice does not prevent xenograft rejection. Exp Neurol. 2014 Apr; 254:90-8.
    View in: PubMed
    Score: 0.016
  109. Regulation of cyclic AMP response element binding and hippocampal plasticity-related genes by peroxisome proliferator-activated receptor a. Cell Rep. 2013 Aug 29; 4(4):724-37.
    View in: PubMed
    Score: 0.015
  110. In vivo evaluation of [(123)I]MNI-420: a novel single photon emission computed tomography radiotracer for imaging of adenosine 2A receptors in brain. Nucl Med Biol. 2013 Apr; 40(3):403-9.
    View in: PubMed
    Score: 0.015
  111. Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease. Sci Rep. 2013; 3:2157.
    View in: PubMed
    Score: 0.015
  112. Kinetic modeling and occupancy measures of the norepinephrine transporters in baboons using single photon emission computed tomography with (123)I-INER. Synapse. 2013 Jan; 67(1):30-41.
    View in: PubMed
    Score: 0.015
  113. Enduring cortical alterations after a single in-vivo treatment of HIV-1 Tat. Neuroreport. 2012 Oct 03; 23(14):825-9.
    View in: PubMed
    Score: 0.014
  114. Testing NF-?B-based therapy in hemiparkinsonian monkeys. J Neuroimmune Pharmacol. 2012 Sep; 7(3):544-56.
    View in: PubMed
    Score: 0.014
  115. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature. 2011 Nov 06; 480(7378):547-51.
    View in: PubMed
    Score: 0.014
  116. Prenatal exposure to MDMA alters noradrenergic neurodevelopment in the rat. Neurotoxicol Teratol. 2012 Jan-Feb; 34(1):206-13.
    View in: PubMed
    Score: 0.013
  117. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis. 2011 Oct; 44(1):38-52.
    View in: PubMed
    Score: 0.013
  118. ?-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and ?-amyloid accumulation. Eur J Neurosci. 2010 Oct; 32(7):1223-38.
    View in: PubMed
    Score: 0.012
  119. Missing pieces in the Parkinson's disease puzzle. Nat Med. 2010 Jun; 16(6):653-61.
    View in: PubMed
    Score: 0.012
  120. Dopaminergic transplantation for Parkinson's disease: current status and future prospects. Ann Neurol. 2009 Nov; 66(5):591-6.
    View in: PubMed
    Score: 0.012
  121. Decreased alpha-synuclein expression in the aging mouse substantia nigra. Exp Neurol. 2009 Dec; 220(2):359-65.
    View in: PubMed
    Score: 0.012
  122. Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiol Dis. 2009 Nov; 36(2):303-11.
    View in: PubMed
    Score: 0.012
  123. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery. 2009 Apr; 64(4):602-12; discussion 612-3.
    View in: PubMed
    Score: 0.011
  124. Association of early experience with neurodegeneration in aged primates. Neurobiol Aging. 2011 Jan; 32(1):151-6.
    View in: PubMed
    Score: 0.011
  125. Doublecortin expression in adult cat and primate cerebral cortex relates to immature neurons that develop into GABAergic subgroups. Exp Neurol. 2009 Apr; 216(2):342-56.
    View in: PubMed
    Score: 0.011
  126. Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Mol Ther. 2008 Oct; 16(10):1737-44.
    View in: PubMed
    Score: 0.011
  127. Age-related changes in glial cells of dopamine midbrain subregions in rhesus monkeys. Neurobiol Aging. 2010 Jun; 31(6):937-52.
    View in: PubMed
    Score: 0.011
  128. Age and region-specific responses of microglia, but not astrocytes, suggest a role in selective vulnerability of dopamine neurons after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure in monkeys. Glia. 2008 Aug 15; 56(11):1199-214.
    View in: PubMed
    Score: 0.011
  129. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A. 2007 Nov 20; 104(47):18754-9.
    View in: PubMed
    Score: 0.010
  130. Deep brain stimulation for treatment of obesity in rats. J Neurosurg. 2007 Oct; 107(4):809-13.
    View in: PubMed
    Score: 0.010
  131. Age-related accumulation of Marinesco bodies and lipofuscin in rhesus monkey midbrain dopamine neurons: relevance to selective neuronal vulnerability. J Comp Neurol. 2007 Jun 10; 502(5):683-700.
    View in: PubMed
    Score: 0.010
  132. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis. 2007 Jul; 27(1):67-76.
    View in: PubMed
    Score: 0.010
  133. Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease. Brain Res. 2007 May 25; 1147:77-88.
    View in: PubMed
    Score: 0.010
  134. Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point. Parkinsonism Relat Disord. 2007; 13 Suppl 3:S469-77.
    View in: PubMed
    Score: 0.010
  135. Proteasome inhibition and Parkinson's disease modeling. Ann Neurol. 2006 Aug; 60(2):260-4.
    View in: PubMed
    Score: 0.009
  136. Survival and early differentiation of human neural stem cells transplanted in a nonhuman primate model of stroke. J Neurosurg. 2006 Jul; 105(1):96-102.
    View in: PubMed
    Score: 0.009
  137. Age-related alterations in GABA(A) receptor subunits in the nonhuman primate hippocampus. Brain Res. 2006 Feb 16; 1073-1074:120-30.
    View in: PubMed
    Score: 0.009
  138. Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol Dis. 2006 Jan; 21(1):165-80.
    View in: PubMed
    Score: 0.009
  139. RNA amplification of bromodeoxyuridine labeled newborn neurons in the monkey hippocampus. J Neurosci Methods. 2005 Jun 15; 144(2):197-201.
    View in: PubMed
    Score: 0.008
  140. Estrogen replacement increases spinophilin-immunoreactive spine number in the prefrontal cortex of female rhesus monkeys. Cereb Cortex. 2004 Feb; 14(2):215-23.
    View in: PubMed
    Score: 0.008
  141. Estrogen increases the number of spinophilin-immunoreactive spines in the hippocampus of young and aged female rhesus monkeys. J Comp Neurol. 2003 Oct 27; 465(4):540-50.
    View in: PubMed
    Score: 0.008
  142. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci. 2003 Sep; 4(9):727-38.
    View in: PubMed
    Score: 0.008
  143. Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats. Neurotoxicol Teratol. 2003 Sep-Oct; 25(5):509-17.
    View in: PubMed
    Score: 0.008
  144. Distribution of high affinity choline transporter immunoreactivity in the primate central nervous system. J Comp Neurol. 2003 Aug 25; 463(3):341-57.
    View in: PubMed
    Score: 0.008
  145. Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration. J Pharmacol Exp Ther. 2003 Jul; 306(1):218-28.
    View in: PubMed
    Score: 0.007
  146. Chronic ischemic stroke model in cynomolgus monkeys: behavioral, neuroimaging and anatomical study. Neurol Res. 2003 Jan; 25(1):68-78.
    View in: PubMed
    Score: 0.007
  147. The immunophilin ligand GPI-1046 does not have neuroregenerative effects in MPTP-treated monkeys. Exp Neurol. 2002 Dec; 178(2):236-42.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.